A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced that ...
Morning Overview on MSN
The Conversation: Review finds Alzheimer’s drugs show limited benefit
A new class of Alzheimer’s drugs promised to be the first treatments that actually slow the disease rather than just manage ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果